Biotechnology - Licensing

Filter

Current filters:

Licensing

Popular Filters

1 to 25 of 378 results

UK cancer charity partners with Asterias Biotherapies on lung cancer vaccine

UK cancer charity partners with Asterias Biotherapies on lung cancer vaccine

15-09-2014

The charity Cancer Research UK and its commercialization arm Cancer Research Technology (CRT), have reached…

Asterias BiotherapeuticsBiotechnologyBioTimeCancer Research TechnologyLicensingOncologyResearchUKVaccines

NeuroVive in $150 million deal with OnCore BioPharma for hep B candidate NVP018

12-09-2014

Swedish mitochondrial medicine firm NeuroVive Pharmaceutical has signed an exclusive global out-licensing…

Anti-viralsBiotechnologyGlobalLicensingNeuroVive PharmaceuticalNVP018OnCore BioPharma

Seattle Genetics and Genmab sign new antibody-drug conjugate deal

Seattle Genetics and Genmab sign new antibody-drug conjugate deal

10-09-2014

Biotech companies Seattle Genetics of the USA and Denmark’s Genmab have entered into an additional…

BiotechnologyGenmabHuMax-TACLicensingOncologyResearchSeattle Genetics

Bristol-Myers returns rights to clazakizumab to Alder BioPharma

Bristol-Myers returns rights to clazakizumab to Alder BioPharma

03-09-2014

USA-based drug developer Alder BioPharmaceuticals says it has regained the worldwide rights to clazakizumab,…

Alder BiopharmaceuticalsAnti-Arthritics/RheumaticsBiotechnologyBristol-Myers SquibbclazakizumabGlobalInflammatory diseasesLicensing

Advaxis and Merck & Co collaborate on prostate cancer

Advaxis and Merck & Co collaborate on prostate cancer

26-08-2014

US cancer immunotherapies firm Advaxis has entered into a clinical trial collaboration agreement with…

AdvaxisADXS-PSABiotechnologyLicensingMerck & CoOncologypembrolizumabResearch

ViaCyte gets $20 million in deal with Janssen

ViaCyte gets $20 million in deal with Janssen

22-08-2014

Privately held US regenerative medicine company ViaCyte has entered into a rights agreement with Janssen…

BiotechnologyDiabetesEndocrine systemFinancialJanssenJohnson & JohnsonLicensingUSAVC-01ViaCyte

Emergent BioSolutions and MorphoSys to co-develop prostate cancer drug candidate ES414

Emergent BioSolutions and MorphoSys to co-develop prostate cancer drug candidate ES414

20-08-2014

US biopharmaceutical firm Emergent BioSolutions and Germany’s MorphoSys have entered into an agreement…

BiotechnologyEmergent BioSolutionsES414GermanyLicensingMOR209/ES414MorphoSysOncologyProstate cancerUSA

Ligand signs Captisol license deal with Avion Pharmaceuticals

Ligand signs Captisol license deal with Avion Pharmaceuticals

15-08-2014

Ligand Pharmaceuticals has signed a commercial license agreement with fellow USA-based Avion Pharmaceuticals,…

Avion PharmaceuticalsBiotechnologyBusiness FinanceCaptisolLicensingLigand PharmaceuticalsUSA

iBio collaborates with Kanematsu Chemicals to target Japanese market

iBio collaborates with Kanematsu Chemicals to target Japanese market

14-08-2014

USA-based iBio Inc and Japan’s Kanematsu Chemicals, part of Kanematsu Corp have entered into a collaboration…

BiotechnologyBusiness FinanceiBio IncJapanKanematsuLicensingPharmacologyVaccines

TNI BioTech and Hubei Qianjiang link up on cancer drug development

TNI BioTech and Hubei Qianjiang link up on cancer drug development

13-08-2014

US biotech firm TNI BioTech has signed a supplemental agreement with China’s Hubei Qianjiang Pharmaceutical…

BiotechnologyBusiness FinanceChinaHubeiLicensingOncologyQianjiang PharmaceuticalResearchTNI BioTechUSA

Galapagos plunges as GSK gives up rights to developmental drug

09-08-2014

Along with presenting first-half 2014 financial results today, Belgian biotech group Galapagos said its…

BiotechnologyFinancialGalapagosGlaxoSmithKlineGSK2586184Inflammatory diseasesLicensing

Theraclone out-licenses HIV bNAbs to Gilead

Theraclone out-licenses HIV bNAbs to Gilead

01-08-2014

US privately-held drug developer Theraclone Sciences has entered into an agreement with biotech major…

Anti-viralsBiotechnologyBusiness FinanceGilead SciencesHIV/AIDSLicensingTheraclone SciencesUSA

Shire in strategic collaboration with ArmaGen for Hunter syndrome

Shire in strategic collaboration with ArmaGen for Hunter syndrome

23-07-2014

Ireland-headquartered drugmaker Shire has entered into an agreement with US privately held biotech company…

AGT-182ArmagenBiotechnologyCNS DiseasesHunter syndromeIrelandLicensingShireUSA

Puma Biotech rockets on new neratinib data; amends deal with Pfizer

Puma Biotech rockets on new neratinib data; amends deal with Pfizer

23-07-2014

US development-stage company Puma Biotechnology saw its share more than triple to $190 in after-hours…

BiotechnologyLicensingneratinibOncologyPB272PfizerPuma BiotechResearchTrastuzumabUSA

Zeltia diversifying its business pharma model to finance R&D pipeline

22-07-2014

PharmaMar, biopharmaceutical company which represents the main affiliate of Spanish Grupo Zeltia is diversifying…

AplidinBiotechnologyChugai PharmaceuticalGP PharmLicensingOncologyPharmaMarPM 1183PolitrateResearchZeltia

PharmaMar and Chugai link up to commercialize Aplidin in Europe

17-07-2014

Spanish drugmaker Zeltia, through its biotech subsidiary PharmaMar, and Japan’s Chugai Pharmaceutical…

AplidinBiotechnologyChugai PharmaceuticalEuropeLicensingOncologyPharmaMarplitidepsinZeltia

Immunocore and Eli Lilly sign $25 million collaboration

Immunocore and Eli Lilly sign $25 million collaboration

16-07-2014

UK-based biotech firm Immunocore and US drug major Eli Lilly today announced they have entered into a…

BiotechnologyEli LillyImmunocoreImmunologyLicensingLillyOncologyUKUSA

AstraZeneca licensing deal validates Synairgen’s approach, say analysts

AstraZeneca licensing deal validates Synairgen’s approach, say analysts

14-07-2014

Anglo-Swedish drug major AstraZeneca’s recent $230 million deal with British respiratory drug development…

AsthmaAstraZenecaBiotechnologyInterferonLicensingRespiratory and PulmonaryRespiratory therapySNG001SynairgenUK

BIND Thera and Amgen end their Accurin collaboration

BIND Thera and Amgen end their Accurin collaboration

03-07-2014

US clinical stage drug developer BIND Therapeutics saw its shares plunge 15.8% to $10.84 in after-hours…

AccurinsAmgenBIND TherapeuticsBiotechnologyLicensingOncology

Debiopharm signs deal with Nobelex Biotech over antibiotics

Debiopharm signs deal with Nobelex Biotech over antibiotics

27-06-2014

Swiss pharma company Debiopharm Group and Canadian biotech company Nobelex Biotech have announced a collaboration…

Antibiotics and Infectious diseasesBiotechnologyCanadaDebiopharmLicensingNobelex Biotech

Merck & Co in new accord with Bionomics for CNS research

Merck & Co in new accord with Bionomics for CNS research

24-06-2014

Australian biotech firm Bionomics has entered into a second exclusive research collaboration and license…

BionomicsBiotechnologyBNC375LicensingMerck & CoNeurologicalResearch

Bayer strikes deal with Dimension Therapeutics to develop hemophilia A gene therapy

23-06-2014

USA-based venture capital;-backed biotech Dimension Therapeutics has entered into a collaboration with…

BayerBiotechnologyDimension TheapeuticsHematologyLicensingResearch

BIND Therapeutics and Roche collaborate on discovery of novel nanomedicines

BIND Therapeutics and Roche collaborate on discovery of novel nanomedicines

19-06-2014

US clinical stage, investor backed biopharma company BIND Therapeutics (Nasdaq: BIND) has entered into…

BIND TherapeuticsBiotechnologyLicensingResearchRoche

Vertex licenses novel influenza treatment VX-787 to Janssen

Vertex licenses novel influenza treatment VX-787 to Janssen

18-06-2014

US biotech firm Vertex Pharmaceuticals has inked a deal with health care giant Johnson & Johnson subsidiary…

Anti-viralsBiotechnologyGlobalHealth Medical PharmaJanssenJohnson & JohnsonLicensingVertex PharmaceuticalsVX-787

1 to 25 of 378 results

Back to top